InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 170659

Saturday, 05/09/2015 2:59:51 PM

Saturday, May 09, 2015 2:59:51 PM

Post# of 345950

Dr. Schwartz is a highly successful business leader with a record of achievement in developing and implementing global licensing strategies to drive business growth. He as consistently achieved excellent results through the relentless pursuit of first- and/or best-in-class opportunities. An in-depth knowledge of drug development, business practices and the fields of oncology and immunology enabled the seamless execution of several key transactions (below) for Bristol-Myers Squibb. Recognized as the driving force behind the resurrection of Bristol-Myers Squibb’s oncology pipeline.
..
• Acquisition of Kosan Biosciences in May 2008
• Acquisition of Adnexus in September 2007

• Completed Compound licensing Agreements with:

- Zymogenetics (January 2009)
- Exelixis (December 2008; Allicense “Breakthrough Alliance of the Year”)
- PDL (August, 2008)
- Endocyte (March, 2006)
- Sunesis (April, 2005)
- Medarex (November, 2004)
- Pierre-Fabre (April, 2004)
- Medarex (December, 2003)

• Completed research-based collaboration agreements with:

- Infinity (December 2009)
- Adnexus Therapeutics (February, 2007; Breakthrough Alliance of 2008 )
- Exelixis (December, 2006)
- Nerviano (February (2006)
• Completed an intellectual property cross-license agreement with Roche/Kosan in February, 2006.
..



Interesting, I've already talked about a few of the deals that Bristol Myers Squibb and Robert H. Schwartz were involved in and I forgot about Exelixis, where Bruce Chabner has shares and more interesting is that Bruce Chabner has ties to Bristol Myers Squibb as well

Disclosures: Bruce A. Chabner: Sanofi, Allergan, Epizyme, PharmaMar, GlaxoSmithKline, Peregrine, Pharmacyclics (C/A); Eli Lilly (H); Gilead, Merck, Epizyme, Curis, Onyx, Bristol-Myers Squibb, Amgen, Celgene, Exelixis, Rigel (OI).

-------------------------------

This may need more looking into, because the puzzle pieces become confusing and I wonder if Bruce Chabner will become a PS Targeting advocate because now I am confused that he does not list Peregrine as a disclosure above ??

time to hit some golf balls and think about it

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News